AbbVie Licenses Lupin’s MALT1 Inhibitor Program, for $977M

 AbbVie Licenses Lupin’s MALT1 Inhibitor Program, for $977M

AbbVie Licenses Lupin’s MALT1 Inhibitor Program, for $977M

Shots:
  • Lupin to receive $30M upfront, up to $947M milestones and royalties on sales. AbbVie to get exclusive worldwide (Ex. India) rights to develop and commercialize Lupin’s MALT1 inhibitors
  • The focus of the agreement is to utilize Lupin’s Drug Discovery platform to develop
    treatments for multiple hematological cancers
  • MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) Inhibitor Program involves protein MALT-1, targeted for the activation of T-cell and B-cell lymphocytes

Click here to read full press release/ article | Ref: Lupin | Image: EvaluatePharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post